Associated Papers
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma.
Shi DD et al.
Cancer Cell, 2022
A novel mutant PIK3R1EY451delinsD breast cancer patient resistant to HER2-targeted therapy treated with everolimus: a case report.
Wang K et al.
Molecular Biology Reports, 2022
Phosphorylation and Driver Mutations in PI3Kα and PTEN Autoinhibition.
Nussinov R et al.
Molecular Cancer Research : Mcr, 2021
Next-generation sequencing analysis of endometrial screening liquid-based cytology specimens: a comparative study to tissue specimens.
Akahane T et al.
Bmc Medical Genomics, 2020
32652986 (PubMed )
Supplement: 12920_2020_753_MOESM1_ESM.xlsx › Sheet1
Neomorphic mutations create therapeutic challenges in cancer.
Takiar V et al.
Oncogene, 2017
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
MacConaill LE et al.
The Journal of Molecular Diagnostics : Jmd, 2014
Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors.
Cheung LW et al.
Cancer Cell, 2014
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.
Cheung LW et al.
Cancer Discovery, 2011
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
Unknown Author
Nature, 2008
Select a paper to view details